Ritivixibat (A3907) Phase 2 Clinical Trial Results
Safety results for the Phase 2 ritivixibat study (A3907) for PSC have been released.
Read MorePSC and GLP-1 Medication for Weight Loss
Exploring the role of GLP-1 medications and what the latest research means for our community.
Read MorePiSCATIN study reaches full recruitment milestone
The PiSCATIN study has enrolled 570 participants, moving us closer to potential PSC treatments.
Read MoreVolunteer Trustees Wanted
Apply to be a Trustee for PSC Support and use your knowledge and skills to help the charity meet the needs of people affected by PSC.
Read MorePSC Support Signs Landmark European Declaration to Accelerate Rare Disease Innovation
PSC Support joins European leaders to advocate for a cohesive ecosystem in rare disease care.
Read MoreFebruary 2026 Research Roundup
A month of leadership growth, breakthrough research, and new milestones in clinical care.
Read MoreRare Disease Day 2026
From a ‘black box’ to a global movement: how we’re accelerating PSC research.
Read MoreHelp Researchers Understand the Impact of Acute Cholangitis
Help researchers understand ‘PSC flares’ by sharing your symptoms in our global survey.
Read MoreDriving Global Change Through the Patient Voice
New global survey results reveal the significant impact of itch on life with PSC.
Read MorePrivacy Policy Update 25 February 2026
We’ve updated our Privacy Policy
Read More